AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29249774
Drug: Lifestyle support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle support program administered by pharmacists (brochures and healthy lifestyle advice using motivational interviewing methods) over a 12-week period
Trial: 12375333
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily tramadol tablets
Trial: 12375333
Drug: Normal release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal release tramadol capsules (50 mg) taken 3 or 4 times daily
Trial: 9951568
Drug: Psychotherapy (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy (weekly interpersonal psychotherapy)
Trial: 2189979
Drug: Daily suction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily suction and débridement with intravenous mezlocillin
Trial: 2189979
Drug: Daily suction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily suction and débridement with intravenous ceftazidime
Trial: 2189979
Drug: Daily suction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily suction and débridement without antibiotics (control)
Trial: 2189979
Drug: All patients
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients treated initially with antibiotics
Trial: 25707
Drug: Tienilic acid
RxNorm normalized name: Tienilic acid
DrugBank: Tienilic acid (DB04831)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tienilic acid (250 mg to 500 mg)
Trial: 25707
Drug: Hydrochlorothiazide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (50 mg to 100 mg)
Trial: 26677829
Drug: Eccentric overload
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eccentric overload training (ECC) group performed 6 weeks of eccentric overload training (twice weekly, 4 sets of 7 repetitions in a Yoyo squat device) before the running intervention.
Trial: 24599421
Drug: Selective estrogen-receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective estrogen-receptor modulators
Trial: 7528129
Drug: β-blockers (general
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-blockers (general use)
Trial: 7528129
Drug: β-blockers (late
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-blockers (late use)
Trial: 7528129
Drug: β-blockers (heart
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-blockers (heart failure)
Trial: 2973571
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg fenoterol hydrobromide
Trial: 30100558
Drug: Triple antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antiplatelet therapy (TAT) with cilostazol
Trial: 27787471
Drug: Plyometric training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plyometric training (20 min·d, twice a week, during 12 weeks)
Trial: 15244255
Drug: CNOP chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNOP chemotherapy
Trial: 7935030
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens with cyclic medrogestone, 5 mg daily during the last 12 days of each 28 days treatment cycle
Trial: 28406752
Drug: PCECV-G (German
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCECV-G (German batch)
Trial: 28406752
Drug: PCECV-I and
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCECV-I and PCECV-G (all groups)
Trial: 16724575
Drug: Fixed bacterium
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed bacterium combination of Lactobacillus gasseri and Bifidobacterium longum
Trial: 7483113
Drug: Tablets containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing 66 mg ferrous iron (as fumarate) daily
Trial: 10922094
Drug: Enema preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enema preparation
Trial: 7083601
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (TU) 160 mg daily by mouth
Trial: 29565951
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL of 0.25% bupivacaine plus 1 µg/kg dexmedetomidine (GD group)
Trial: 29565951
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL of 0.25% bupivacaine only (GB group)
Trial: 27436880
Drug: Pravastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin treatment arm
Trial: 24798770
Drug: dolutegravir/abacavir/lamivudine FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dolutegravir/abacavir/lamivudine FDC tablet
Trial: 24798770
Drug: dolutegravir/abacavir/lamivudine FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dolutegravir/abacavir/lamivudine FDC tablet with a high-fat meal
Trial: 11887531
Drug: Atraumatic restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic restorative treatment (ART) for Class I cavity preparations
Trial: 11887531
Drug: Atraumatic restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic restorative treatment (ART) for Class II cavity preparations
Trial: 11887531
Drug: Conventional cavity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cavity preparation for Class II cavity preparations
Trial: 11887531
Drug: Conventional cavity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cavity preparation for Class I cavity preparations
Trial: 11887531
Drug: Amalgam restorations
RxNorm normalized name: DENTAL AMALGAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amalgam restorations in Class I conventional preparations
Trial: 9790334
Drug: rhGH (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH (0.2 mg/kg/day subcutaneously)
Trial: 7631514
Drug: High-dose Edmonston-Zagreb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Edmonston-Zagreb strain (10(5.6) TDIC50)
Trial: 7631514
Drug: Low-dose Connaught
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Connaught strain (10(3) TCID50)
Trial: 7631514
Drug: Medium-dose Schwarz
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose Schwarz strain (10(4) TCID50)
Trial: 319717
Drug: Aerosolized delta9-tetrahydrocannabinol
RxNorm normalized name: delta9-tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosolized delta9-tetrahydrocannabinol (5 to 20 mg)
Trial: 319717
Drug: Aerosolized delta9-tetrahydrocannabinol
RxNorm normalized name: delta9-tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosolized delta9-tetrahydrocannabinol (5 mg)
Trial: 19164402
Drug: Group exercise
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group exercise held twice weekly for five weeks
Trial: 16467067
Drug: Nebulised bronchodilator
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised bronchodilator (ipratropium 0.5 mg + salbutamol 2.5 mg) with 50% O2
Trial: 16467067
Drug: Nebulised bronchodilator
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised bronchodilator (ipratropium 0.5 mg + salbutamol 2.5 mg) alone
Trial: 12468808
Drug: Amitriptyline (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (titrated from 10 to 75 mg in extended-release form)
Trial: 7698617
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg t.i.d. for 2 weeks (group O)
Trial: 7698617
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg t.i.d. + Amoxicillin 500 mg q.i.d. for 2 weeks (group O + A)
Trial: 23134
Drug: Oral theophylline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral theophylline, placebo aerosol (TP)
Trial: 23134
Drug: Oral placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo, rimiterol aerosol (PR)
Trial: 23134
Drug: Oral theophylline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral theophylline, rimiterol aerosol (TR)
Trial: 23134
Drug: Oral placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo, placebo aerosol (PP)
Trial: 30186989
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with ceftizoxime powder and clotrimazole ointment
Trial: 19681572
Drug: 6-week restorative
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6-week restorative care educational program (30 minutes weekly)
Trial: 15113639
Drug: Cost-sharing group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost-sharing group (essential drugs)
Trial: 15113639
Drug: Cost-sharing group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost-sharing group (non-essential drugs)
Trial: 15113639
Drug: Non cost-sharing
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non cost-sharing group (essential drugs)
Trial: 15113639
Drug: Non cost-sharing
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non cost-sharing group (non-essential drugs)
Trial: 15113639
Drug: Prescriptions above
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescriptions above the upper bound of the cost-sharing schedule
Trial: 7706571
Drug: AT III
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT III concentrates administered at an initial dose of 60 U/kg followed by 10 U/kg every six hours
Trial: 7706571
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment with AT III)
Trial: 3123116
Drug: Combined glyburide-insulin
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined glyburide-insulin therapy
Trial: 29380128
Drug: Fexapotide triflutate
RxNorm normalized name: Corticorelin Ovine Triflutate
DrugBank: Corticorelin ovine triflutate (DB09067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexapotide triflutate 2.5 mg transrectal injectable (FT)
Trial: 27272079
Drug: Clindamycin‐BP 3.75%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin‐BP 3.75% gel
Trial: 27272079
Drug: Adapalene 0.3%‐BP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene 0.3%‐BP 2.5% gel
Trial: 20839440
Drug: TCM-WM treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCM-WM treatment group
Trial: 18031547
Drug: High trough
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High trough plasma VPA concentrations (above 100 microg/ml for women, above 130 microg/ml for men)
Trial: 16159735
Drug: Single treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single treatment with PDT using topical methyl aminolevulinate (MAL)
Trial: 16159735
Drug: Two treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two treatments of MAL-PDT 1 week apart
Trial: 11286374
Drug: Medical Resonance
RxNorm normalized name: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical Resonance Therapy Music (MRT‐Music)
Trial: 1438624
Drug: dl-fenfluramine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dl-fenfluramine (1.0 mg/kg)
Trial: 3895409
Drug: Topical streptokinase‐streptodornase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical streptokinase‐streptodornase (Varidase) solution
Trial: 26809253
Drug: Insulin Detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin Detemir (second period)
Trial: 26809253
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin Glargine (switched to Insulin Detemir)
Trial: 24684165
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination cream with fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% plus sunscreen pre-treatment for 2 weeks.
Trial: 24147129
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (sham analgesic cream)
Trial: 18339032
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E and selenium supplementation (Vitamin E: 140 mg alpha‐tocopherol and selenium: 200 microg)
Trial: 14623531
Drug: Letrozole (aromatase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (aromatase inhibitor) with testosterone
Trial: 10873072
Drug: Anastrozole (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole (both doses combined)
Trial: 1424202
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (40 mg daily for 3 months)
Trial: 2412054
Drug: Specific serotonergic
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific serotonergic antagonists (oral or intravenous)
Trial: 27817128
Drug: L-arginine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine with vitamins B6, folic acid and B12 (Telcor® Arginin plus)
Trial: 24752034
Drug: Motive-oriented therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motive-oriented therapeutic relationship (MOTR) added to general psychiatric management (GPM) treatment
Trial: 24752034
Drug: General psychiatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General psychiatric management (GPM) treatment
Trial: 22759549
Drug: 2% Chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% Chlorhexidine gluconate (CHG) applied thrice-weekly
Trial: 20454851
Drug: IgPro20 (20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgPro20 (20% liquid SCIG) administered weekly
Trial: 12030952
Drug: Oral beclometasone
RxNorm normalized name: beclomethasone Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral beclometasone dipropionate (BDP) 5 mg/day plus 5‐ASA 3.2 g/day
Trial: 12030952
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus 5‐ASA 3.2 g/day
Trial: 18382886
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor therapy
Trial: 7552537
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin 750 mg x 2 p.o.
Trial: 7552537
Drug: Intravenous cefuroxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cefuroxime 1.5 g x 3 i.v. on the day of surgery
Trial: 1310566
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g of WSDF/day consisting of psyllium husk, pectin, and guar and locust bean gums for 4 weeks
Trial: 1310566
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of WSDF/day from high-viscosity guar gum for 4 weeks
Trial: 1310566
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g of WSDF/day
Trial: 1310566
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g of WSDF/day
Trial: 17105779
Drug: Eligibility criteria
RxNorm normalized name: DIMETHICONE 1 g in 100 mL TOPICAL GEL [JAFRA Fruteria So Citrico]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligibility criteria for major asthma RCTs (on treatment)
Trial: 16366758
Drug: venlafaxine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: venlafaxine (150 to 225 mg daily, titrated based on symptoms) + behavioral counseling + transdermal nicotine replacement therapy (22 mg/day)
Trial: 16366758
Drug: placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo + behavioral counseling + transdermal nicotine replacement therapy (22 mg/day)
Trial: 7546831
Drug: Serotonin antagonists
RxNorm normalized name: Serotonin antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonin antagonists (ondansetron, granisetron, tropisetron)
Trial: 7546831
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of steroids and dopamine D2 antagonist metopimazine
Trial: 7011085
Drug: 0.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg of hydrallazine
Trial: 28283340
Drug: IV push
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV push low dose ketamine (0.3 mg/kg)
Trial: 28283340
Drug: Short infusion
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short infusion low dose ketamine (0.3 mg/kg)
Trial: 27009433
Drug: Geneva cocktail
RxNorm normalized name: amiodarone
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Geneva cocktail (combination of low‐dose caffeine, flurbiprofen, omeprazole, dextromethorphan, midazolam, fexofenadine, bupropion)
Trial: 27009433
Drug: CYP probes
RxNorm normalized name: estradiol cypionate / testosterone cypionate Injectable Solution [Duo-Cyp]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP probes administered alone
Trial: 25080037
Drug: Test implant
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test implant (4.5-mm-diameter moderately roughened implant with a rounded 6-mm abutment)
Trial: 25080037
Drug: Control implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control implant (3.75-mm diameter as-machined implant with a conically shaped 5.5-mm abutment)
Trial: 19309367
Drug: Long-pulsed dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-pulsed dye laser (LPDL) treatment (V‐beam Perfecta, 595 nm)
Trial: 19309367
Drug: Intense pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense pulsed light (IPL) treatment (Ellipse Flex)
Trial: 17311692
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with paclitaxel (200 mg/m2) and carboplatin (AUC 6) followed by observation
Trial: 17311692
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with paclitaxel (200 mg/m2) and carboplatin (AUC 6) followed by radiation therapy (RT) at 5000 cGy in 25 fractions over 5 weeks
Trial: 15206988
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg fosfluconazole once daily for 14 days
Trial: 15206988
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg fluconazole once daily for 14 days
Trial: 15206988
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg fosfluconazole once daily for 10 days (no loading dose)
Trial: 15206988
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of 1000 mg on day 1 followed by 500 mg for 9 days (one loading dose)
Trial: 15206988
Drug: Loading doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading doses of 1000 mg on days 1 and 2 followed by 500 mg for 8 days (two loading doses)
Trial: 28938877
Drug: Metformin and
RxNorm normalized name: metformin and acarbose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin and insulin (n=10)
Trial: 24733715
Drug: Nocturnal oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nocturnal oxygen therapy (NOT) at 3.0 l/min
Trial: 24733715
Drug: No nocturnal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No nocturnal oxygen therapy (no NOT)
Trial: 21506190
Drug: Sage leaf
RxNorm normalized name: sage leaf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sage leaf extract (500 mg capsule every 8 hours for 2 months)
Trial: 19565667
Drug: Caudal 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal 0.25% levobupivacaine (1 ml.kg(‐1)) alone
Trial: 12622344
Drug: Lorazepam (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (2.0 mg/70 kg orally administered)
Trial: 12622344
Drug: Scopolamine (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (0.6 mg/70 kg subcutaneously administered)
Trial: 3751450
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (protocol B, without hemorheologic treatment)